WO2013066438A2
(en)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
US11021737B2
(en)
|
2011-12-22 |
2021-06-01 |
President And Fellows Of Harvard College |
Compositions and methods for analyte detection
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
EP3272356A1
(en)
|
2012-02-24 |
2018-01-24 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for the treatment of hemoglobinopathies
|
LT3401400T
(lt)
|
2012-05-25 |
2019-06-10 |
The Regents Of The University Of California |
Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui
|
ES2812599T3
(es)
|
2012-08-29 |
2021-03-17 |
Sangamo Therapeutics Inc |
Procedimientos y composiciones para el tratamiento de una afección genética
|
PT3502240T
(pt)
|
2012-11-27 |
2021-08-11 |
Childrens Medical Ct Corp |
Elementos reguladores distais de bcl11a como alvo para a reindução de hemoglobina fetal
|
EP3138911B1
(en)
|
2012-12-06 |
2018-12-05 |
Sigma Aldrich Co. LLC |
Crispr-based genome modification and regulation
|
ES2658401T3
(es)
|
2012-12-12 |
2018-03-09 |
The Broad Institute, Inc. |
Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas
|
CA3081054A1
(en)
|
2012-12-17 |
2014-06-26 |
President And Fellows Of Harvard College |
Rna-guided human genome engineering
|
US10138509B2
(en)
|
2013-03-12 |
2018-11-27 |
President And Fellows Of Harvard College |
Method for generating a three-dimensional nucleic acid containing matrix
|
KR101780885B1
(ko)
|
2013-03-14 |
2017-10-11 |
카리부 바이오사이언시스 인코포레이티드 |
핵산-표적화 핵산의 조성물 및 방법
|
CA2906553C
(en)
|
2013-03-15 |
2022-08-02 |
The General Hospital Corporation |
Rna-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
EP4286517A3
(en)
|
2013-04-04 |
2024-03-13 |
President and Fellows of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
CA2910489A1
(en)
*
|
2013-05-15 |
2014-11-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
US20140356956A1
(en)
|
2013-06-04 |
2014-12-04 |
President And Fellows Of Harvard College |
RNA-Guided Transcriptional Regulation
|
DK3011032T3
(da)
|
2013-06-17 |
2020-01-20 |
Broad Inst Inc |
Fremføring, modificering og optimering af systemer, fremgangsmåder og sammensætninger til målretning mod og modellering af sygdomme og forstyrrelser i postmitotiske celler
|
KR20160030187A
(ko)
|
2013-06-17 |
2016-03-16 |
더 브로드 인스티튜트, 인코퍼레이티드 |
간의 표적화 및 치료를 위한 CRISPRCas 시스템, 벡터 및 조성물의 전달 및 용도
|
EP3011034B1
(en)
|
2013-06-17 |
2019-08-07 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
US10011850B2
(en)
|
2013-06-21 |
2018-07-03 |
The General Hospital Corporation |
Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
|
EP3019595A4
(en)
|
2013-07-09 |
2016-11-30 |
|
THERAPEUTIC USES OF A GENERIC CHANGE WITH CRISPR / CAS SYSTEMS
|
CN105517579B
(zh)
|
2013-07-10 |
2019-11-15 |
哈佛大学校长及研究员协会 |
用于RNA向导的基因调节和编辑的正交Cas9蛋白
|
US11306328B2
(en)
|
2013-07-26 |
2022-04-19 |
President And Fellows Of Harvard College |
Genome engineering
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
LT3066201T
(lt)
|
2013-11-07 |
2018-08-10 |
Editas Medicine, Inc. |
Su crispr susiję būdai ir kompozicijos su valdančiomis grnr
|
EP3960856A1
(en)
*
|
2013-11-13 |
2022-03-02 |
Children's Medical Center Corporation |
Nuclease-mediated regulation of gene expression
|
EP3071695A2
(en)
*
|
2013-11-18 |
2016-09-28 |
Crispr Therapeutics AG |
Crispr-cas system materials and methods
|
US9074199B1
(en)
|
2013-11-19 |
2015-07-07 |
President And Fellows Of Harvard College |
Mutant Cas9 proteins
|
US10787684B2
(en)
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
MX2016007327A
(es)
|
2013-12-12 |
2017-03-06 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para dirigirlos a trastornos y enfermedades usando componentes para suministro de particulas.
|
KR20160089527A
(ko)
|
2013-12-12 |
2016-07-27 |
더 브로드 인스티튜트, 인코퍼레이티드 |
게놈 편집을 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료적 응용
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
WO2015103153A1
(en)
*
|
2013-12-31 |
2015-07-09 |
The Regents Of The University Of California |
Cas9 crystals and methods of use thereof
|
WO2015105928A1
(en)
*
|
2014-01-08 |
2015-07-16 |
President And Fellows Of Harvard College |
Rna-guided gene drives
|
CN106232814B
(zh)
|
2014-02-13 |
2021-05-11 |
宝生物工程(美国)有限公司 |
从核酸的初始集合中耗尽靶分子的方法、以及用于实践其的组合物和试剂盒
|
EP3553176A1
(en)
|
2014-03-10 |
2019-10-16 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
EP3122880B1
(en)
*
|
2014-03-26 |
2021-05-05 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
JP2017511132A
(ja)
*
|
2014-03-26 |
2017-04-20 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
ヒト造血幹/前駆細胞のエクスビボ拡大のための組成物および方法
|
WO2015148860A1
(en)
*
|
2014-03-26 |
2015-10-01 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating beta-thalassemia
|
BR112016024565A2
(pt)
|
2014-04-25 |
2018-01-23 |
Children's Medical Center Corporation |
composições e métodos de tratar hemoglobinopatias
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
US11071289B2
(en)
*
|
2014-08-14 |
2021-07-27 |
Biocytogen Boston Corp |
DNA knock-in system
|
CA2957737A1
(en)
|
2014-09-07 |
2016-03-10 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
|
ES2886012T3
(es)
|
2014-09-16 |
2021-12-16 |
Sangamo Therapeutics Inc |
Métodos y composiciones para la ingeniería y corrección de genomas mediadas por nucleasas en células madre hematopoyéticas
|
CN113016623A
(zh)
|
2014-09-26 |
2021-06-25 |
谱赛科美国股份有限公司 |
用于甜菊的单核苷酸多态性(snp)标志物
|
KR20240013283A
(ko)
|
2014-12-03 |
2024-01-30 |
애질런트 테크놀로지스, 인크. |
화학적 변형을 갖는 가이드 rna
|
WO2016094872A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
EP3985115A1
(en)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
EP3247366A4
(en)
*
|
2015-01-21 |
2018-10-31 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
US10626372B1
(en)
|
2015-01-26 |
2020-04-21 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
EP3262172A2
(en)
*
|
2015-02-23 |
2018-01-03 |
Crispr Therapeutics AG |
Materials and methods for treatment of hemoglobinopathies
|
US20180200387A1
(en)
*
|
2015-02-23 |
2018-07-19 |
Crispr Therapeutics Ag |
Materials and methods for treatment of human genetic diseases including hemoglobinopathies
|
JP6873911B2
(ja)
|
2015-04-06 |
2021-05-19 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
初代細胞において標的核酸の遺伝子調節を誘導するためにインビトロで行う方法
|
US10155938B2
(en)
*
|
2015-04-14 |
2018-12-18 |
City Of Hope |
Coexpression of CAS9 and TREX2 for targeted mutagenesis
|
CN104805118A
(zh)
*
|
2015-04-22 |
2015-07-29 |
扬州大学 |
一种苏禽黄鸡胚胎干细胞特定基因进行靶向敲除方法
|
CN108026566A
(zh)
*
|
2015-05-04 |
2018-05-11 |
特拉维夫大学拉莫特有限公司 |
用于使dna片段化的方法和试剂盒
|
ES2835861T3
(es)
*
|
2015-05-08 |
2021-06-23 |
Childrens Medical Ct Corp |
Direccionamiento de regiones funcionales del potenciador de BCL11A para la reinducción de hemoglobina fetal
|
JP7030522B2
(ja)
*
|
2015-05-11 |
2022-03-07 |
エディタス・メディシン、インコーポレイテッド |
幹細胞における遺伝子編集のための最適化crispr/cas9システムおよび方法
|
WO2016201047A1
(en)
|
2015-06-09 |
2016-12-15 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
EP3310931B1
(en)
|
2015-06-17 |
2021-11-17 |
The UAB Research Foundation |
Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
|
AU2016278982A1
(en)
*
|
2015-06-17 |
2018-01-18 |
The Uab Research Foundation |
CRISPR/Cas9 complex for genomic editing
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
JP6799586B2
(ja)
|
2015-08-28 |
2020-12-16 |
ザ ジェネラル ホスピタル コーポレイション |
遺伝子操作CRISPR−Cas9ヌクレアーゼ
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
US9897378B2
(en)
|
2015-10-08 |
2018-02-20 |
Nyc Designed Inspirations Llc |
Cosmetic makeup sponge/blender container
|
EP3365357B1
(en)
|
2015-10-23 |
2024-02-14 |
President and Fellows of Harvard College |
Evolved cas9 proteins for gene editing
|
CA3003433A1
(en)
*
|
2015-10-27 |
2017-05-04 |
Children's Hospital Medical Center |
Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and/or genetic manipulation
|
JP6882282B2
(ja)
|
2015-11-03 |
2021-06-02 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
三次元核酸含有マトリックスの立体撮像のための方法と装置
|
WO2017077394A2
(en)
*
|
2015-11-04 |
2017-05-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
CN108368520B
(zh)
|
2015-11-04 |
2023-01-17 |
菲特治疗公司 |
多能细胞的基因组工程改造
|
CA3003152A1
(en)
*
|
2015-11-04 |
2017-05-11 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
JP2019500043A
(ja)
*
|
2015-12-28 |
2019-01-10 |
ノバルティス アーゲー |
異常ヘモグロビン症の治療用組成物および方法
|
CN108884448B
(zh)
|
2016-01-27 |
2022-12-30 |
昂克诺斯公司 |
溶瘤病毒载体及其用途
|
US11530253B2
(en)
|
2016-02-25 |
2022-12-20 |
The Children's Medical Center Corporation |
Customized class switch of immunoglobulin genes in lymphoma and hybridoma by CRISPR/CAS9 technology
|
EP3430142A1
(en)
*
|
2016-03-14 |
2019-01-23 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating beta hemoglobinopathies
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
CN109715198B
(zh)
*
|
2016-04-18 |
2022-09-06 |
克里斯珀医疗股份公司 |
用于治疗血红蛋白病的材料和方法
|
EP3449016A4
(en)
|
2016-04-25 |
2019-10-02 |
President and Fellows of Harvard College |
HYBRIDIZATION CHAIN REACTION PROCESS FOR IN-SITU MOLECULE DETECTION
|
WO2017191503A1
(en)
*
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
EP3487994A4
(en)
*
|
2016-07-25 |
2020-01-29 |
Bluebird Bio, Inc. |
BCL11A HOMING ENDONUCLEASE VERSIONS, COMPOSITIONS AND METHODS OF USE
|
AU2017306676B2
(en)
|
2016-08-03 |
2024-02-22 |
President And Fellows Of Harvard College |
Adenosine nucleobase editors and uses thereof
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
AU2017308889B2
(en)
|
2016-08-09 |
2023-11-09 |
President And Fellows Of Harvard College |
Programmable Cas9-recombinase fusion proteins and uses thereof
|
CN106244555A
(zh)
*
|
2016-08-23 |
2016-12-21 |
广州医科大学附属第三医院 |
一种提高基因打靶的效率的方法及β‑球蛋白基因位点的碱基原位修复方法
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
IL265045B2
(en)
|
2016-09-08 |
2023-09-01 |
Bluebird Bio Inc |
Variants of endonuclease pd-1, compositions and methods of use
|
SG11201903089RA
(en)
|
2016-10-14 |
2019-05-30 |
Harvard College |
Aav delivery of nucleobase editors
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
WO2018140791A1
(en)
|
2017-01-27 |
2018-08-02 |
Children's Hospital Medical Center |
Methods of enhancing engraftment activity of hematopoietic stem cells
|
TW201839136A
(zh)
*
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
US11542496B2
(en)
|
2017-03-10 |
2023-01-03 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
EP3596217A1
(en)
|
2017-03-14 |
2020-01-22 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
IL306092A
(en)
|
2017-03-23 |
2023-11-01 |
Harvard College |
Nucleic base editors that include nucleic acid programmable DNA binding proteins
|
WO2018195545A2
(en)
|
2017-04-21 |
2018-10-25 |
The General Hospital Corporation |
Variants of cpf1 (cas12a) with altered pam specificity
|
WO2018200597A1
(en)
*
|
2017-04-24 |
2018-11-01 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Homology directed repair compositions for the treatment of hemoglobinopathies
|
EP3622070A2
(en)
|
2017-05-10 |
2020-03-18 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
WO2018218166A1
(en)
|
2017-05-25 |
2018-11-29 |
The General Hospital Corporation |
Using split deaminases to limit unwanted off-target base editor deamination
|
US11788087B2
(en)
|
2017-05-25 |
2023-10-17 |
The Children's Medical Center Corporation |
BCL11A guide delivery
|
WO2018220210A1
(en)
*
|
2017-06-02 |
2018-12-06 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant lentiviral vector for stem cell-based gene therapy of sickle cell disorder
|
WO2019014564A1
(en)
|
2017-07-14 |
2019-01-17 |
Editas Medicine, Inc. |
SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
|
EP3658165A4
(en)
|
2017-07-26 |
2021-09-01 |
Oncorus, Inc. |
ONCOLYTIC VIRUS VECTORS AND USES THEREOF
|
JP2020534795A
(ja)
|
2017-07-28 |
2020-12-03 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
WO2019070974A1
(en)
|
2017-10-04 |
2019-04-11 |
Bluebird Bio, Inc. |
PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
|
JP7427584B2
(ja)
|
2017-10-13 |
2024-02-05 |
セレクタ バイオサイエンシーズ インコーポレーテッド |
抗ウイルス導入ベクターigm応答を減弱化するための方法および組成物
|
US11795443B2
(en)
|
2017-10-16 |
2023-10-24 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
MA50849A
(fr)
*
|
2017-10-26 |
2020-09-02 |
Vertex Pharma |
Substances et procédés pour le traitement d'hémoglobinopathies
|
CN109722415B
(zh)
*
|
2017-10-27 |
2021-01-26 |
博雅辑因(北京)生物科技有限公司 |
一种造血干细胞的培养组合物、培养基以及造血干细胞的培养方法
|
AU2018378479A1
(en)
*
|
2017-12-05 |
2020-06-18 |
Vertex Pharmaceuticals Incorporated |
CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof
|
EP3749768A1
(en)
|
2018-02-05 |
2020-12-16 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
US11566236B2
(en)
|
2018-02-05 |
2023-01-31 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
WO2019165436A1
(en)
|
2018-02-26 |
2019-08-29 |
Antolrx |
Tolerogenic liposomes and methods of use thereof
|
US10968257B2
(en)
|
2018-04-03 |
2021-04-06 |
The Broad Institute, Inc. |
Target recognition motifs and uses thereof
|
JP2021521838A
(ja)
*
|
2018-04-27 |
2021-08-30 |
シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) |
ブルトン型チロシンキナーゼに対するtalenベースのおよびcrispr/casベースのゲノム編集
|
US20200102563A1
(en)
*
|
2018-10-02 |
2020-04-02 |
Exosome Therapeutics, Inc. |
Exosome loaded therapeutics for treating sickle cell disease
|
CA3122278A1
(en)
*
|
2018-12-10 |
2020-06-18 |
Bluebird Bio, Inc. |
Homing endonuclease variants
|
CA3124110A1
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Crispr-associated transposase systems and methods of use thereof
|
US11946040B2
(en)
|
2019-02-04 |
2024-04-02 |
The General Hospital Corporation |
Adenine DNA base editor variants with reduced off-target RNA editing
|
US20220235347A1
(en)
*
|
2019-02-13 |
2022-07-28 |
Beam Therapeutics Inc. |
Compositions and methods for treating hemoglobinopathies
|
JP2022526908A
(ja)
|
2019-03-19 |
2022-05-27 |
ザ ブロード インスティテュート,インコーポレーテッド |
編集ヌクレオチド配列を編集するための方法および組成物
|
CN110042124A
(zh)
*
|
2019-04-25 |
2019-07-23 |
国家卫生健康委科学技术研究所 |
基因组碱基编辑增加人红细胞中胎儿血红蛋白水平的试剂盒及应用
|
CA3138029A1
(en)
*
|
2019-04-30 |
2020-11-05 |
Edigene Inc. |
Method for predicting effectiveness of treatment of hemoglobinopathy
|
CN111939271A
(zh)
*
|
2019-04-30 |
2020-11-17 |
博雅辑因(北京)生物科技有限公司 |
一种血红蛋白病治疗有效性预测方法
|
US20200390718A1
(en)
|
2019-05-28 |
2020-12-17 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuated anti-viral transfer vector immune response
|
CN114072518A
(zh)
*
|
2019-06-28 |
2022-02-18 |
Asc治疗公司 |
用于治疗地中海贫血或镰状细胞病的方法和组合物
|
JP2022550599A
(ja)
|
2019-10-03 |
2022-12-02 |
アーティサン ディベロップメント ラブズ インコーポレイテッド |
操作されたデュアルガイド核酸を有するcrisprシステム
|
WO2021097350A1
(en)
*
|
2019-11-15 |
2021-05-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeted integration at alpha-globin locus in human hematopoietic stem and progenitor cells
|
CN112979823B
(zh)
*
|
2019-12-18 |
2022-04-08 |
华东师范大学 |
一种用于治疗和/或预防β血红蛋白病的产品及融合蛋白
|
AU2021267940A1
(en)
|
2020-05-08 |
2022-12-08 |
President And Fellows Of Harvard College |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
WO2021228944A1
(en)
*
|
2020-05-13 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Base editing approaches for the treatment of betahemoglobinopathies
|
CA3202889A1
(en)
*
|
2020-12-21 |
2022-06-30 |
Jordan JARJOUR |
Compositions and methods for site-directed mutagenesis
|
AU2022235341A1
(en)
|
2021-03-12 |
2023-09-21 |
Mendus B.V. |
Methods of vaccination and use of cd47 blockade
|
WO2022256448A2
(en)
|
2021-06-01 |
2022-12-08 |
Artisan Development Labs, Inc. |
Compositions and methods for targeting, editing, or modifying genes
|
CN113481184A
(zh)
*
|
2021-08-06 |
2021-10-08 |
北京大学 |
融合蛋白以及其使用方法
|
AU2022343300A1
(en)
|
2021-09-10 |
2024-04-18 |
Agilent Technologies, Inc. |
Guide rnas with chemical modification for prime editing
|
WO2023064367A1
(en)
|
2021-10-12 |
2023-04-20 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
WO2023167882A1
(en)
|
2022-03-01 |
2023-09-07 |
Artisan Development Labs, Inc. |
Composition and methods for transgene insertion
|
US20230357437A1
(en)
|
2022-03-09 |
2023-11-09 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
CN114457119B
(zh)
*
|
2022-04-11 |
2022-08-12 |
中吉智药(南京)生物技术有限公司 |
慢病毒载体在制备治疗β-地中海贫血药物中的应用
|
EP4273242A1
(en)
*
|
2022-05-03 |
2023-11-08 |
ETH Zurich |
Crispr-based modification of human hbd gene
|